Literature DB >> 19915522

Generation of induced pluripotent stem cells by reprogramming mouse embryonic fibroblasts with a four transcription factor, doxycycline inducible lentiviral transduction system.

Brad Hamilton1, Qiang Feng, Mike Ye, G Grant Welstead.   

Abstract

Using a defined set of transcription factors and cell culture conditions, Yamanaka and colleagues demonstrated that retrovirus-mediated delivery and expression of Oct4, Sox2, c-Myc, and Klf4 is capable of inducing pluripotency in mouse fibroblasts.(1) Subsequent reports have demonstrated the utility of the doxycycline (DOX) inducible lentiviral delivery system for the generation of both primary and secondary iPS cells from a variety of other adult mouse somatic cell types.(2,3) Induced pluripotent stem (iPS) cells are similar to embryonic stem (ES) cells in morphology, proliferation and ability to induce teratoma formation. Both types of cell can be used as the pluripotent starting material for the generation of differentiated cells or tissues in regenerative medicine.(4-6) iPS cells also have a distinct advantage over ES cells as they exhibit key properties of ES cells without the ethical dilemma of embryo destruction. Here we demonstrate the protocol for reprogramming mouse embryonic fibroblast (MEF) cells with the Stemgent DOX Inducible Mouse TF Lentivirus Set. We also demonstrate that the Stemgent DOX Inducible Mouse TF Lentivirus Set is capable of expressing each of the four transcription factors upon transduction into MEFs thereby inducing a pluripotent stem cell state that displays the pluripotency markers characteristic of ES cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19915522      PMCID: PMC3157852          DOI: 10.3791/1447

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  6 in total

1.  Generation of pluripotent stem cells from adult mouse liver and stomach cells.

Authors:  Takashi Aoi; Kojiro Yae; Masato Nakagawa; Tomoko Ichisaka; Keisuke Okita; Kazutoshi Takahashi; Tsutomu Chiba; Shinya Yamanaka
Journal:  Science       Date:  2008-02-14       Impact factor: 47.728

Review 2.  Therapeutic potential of embryonic stem cells.

Authors:  Paul H Lerou; George Q Daley
Journal:  Blood Rev       Date:  2005-11       Impact factor: 8.250

3.  Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors.

Authors:  Kazutoshi Takahashi; Shinya Yamanaka
Journal:  Cell       Date:  2006-08-10       Impact factor: 41.582

Review 4.  Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development.

Authors:  Charles E Murry; Gordon Keller
Journal:  Cell       Date:  2008-02-22       Impact factor: 41.582

5.  Induced pluripotent stem cell lines derived from human somatic cells.

Authors:  Junying Yu; Maxim A Vodyanik; Kim Smuga-Otto; Jessica Antosiewicz-Bourget; Jennifer L Frane; Shulan Tian; Jeff Nie; Gudrun A Jonsdottir; Victor Ruotti; Ron Stewart; Igor I Slukvin; James A Thomson
Journal:  Science       Date:  2007-11-20       Impact factor: 47.728

6.  In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state.

Authors:  Marius Wernig; Alexander Meissner; Ruth Foreman; Tobias Brambrink; Manching Ku; Konrad Hochedlinger; Bradley E Bernstein; Rudolf Jaenisch
Journal:  Nature       Date:  2007-06-06       Impact factor: 49.962

  6 in total
  6 in total

1.  Simple derivation of transgene-free iPS cells by a dual recombinase approach.

Authors:  Anna Pertek; Florian Meier; Martin Irmler; Johannes Beckers; Stavroula Skylaki; Max Endele; Wolfgang Wurst; Nilima Prakash; Ralf Kühn
Journal:  Mol Biotechnol       Date:  2014-08       Impact factor: 2.695

Review 2.  Myb proteins: angels and demons in normal and transformed cells.

Authors:  Ye Zhou; Scott A Ness
Journal:  Front Biosci (Landmark Ed)       Date:  2011-01-01

Review 3.  Neoantigen Specific T Cells Derived From T Cell-Derived Induced Pluripotent Stem Cells for the Treatment of Hepatocellular Carcinoma: Potential and Challenges.

Authors:  Fei Lu; Xiao-Jing-Nan Ma; Wei-Lin Jin; Yang Luo; Xun Li
Journal:  Front Immunol       Date:  2021-05-13       Impact factor: 7.561

4.  Mesenchymal Progenitor Cells and Their Orthopedic Applications: Forging a Path towards Clinical Trials.

Authors:  Deana S Shenaq; Farbod Rastegar; Djuro Petkovic; Bing-Qiang Zhang; Bai-Cheng He; Liang Chen; Guo-Wei Zuo; Qing Luo; Qiong Shi; Eric R Wagner; Enyi Huang; Yanhong Gao; Jian-Li Gao; Stephanie H Kim; Ke Yang; Yang Bi; Yuxi Su; Gaohui Zhu; Jinyong Luo; Xiaoji Luo; Jiaqiang Qin; Russell R Reid; Hue H Luu; Rex C Haydon; Tong-Chuan He
Journal:  Stem Cells Int       Date:  2010-12-16       Impact factor: 5.443

5.  The Use of Trichostatin A during Pluripotent Stem Cell Generation Does Not Affect MHC Expression Level.

Authors:  Sara Farahi; Sara Hosseini; Hossein Ghanbarian; Seyed Mahmoud Hashemi; Mohammad Salehi; Samaneh Hosseini
Journal:  Stem Cells Int       Date:  2022-02-15       Impact factor: 5.443

6.  Formation of Osteochondral Organoids from Murine Induced Pluripotent Stem Cells.

Authors:  Shannon K O'Connor; Dakota B Katz; Sara J Oswald; Logan Groneck; Farshid Guilak
Journal:  Tissue Eng Part A       Date:  2020-12-22       Impact factor: 4.080

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.